Targeting BRAF dimerization in cancer: structural insights and therapeutic strategies beyond monomer inhibition.

Authors

Jayhind Bharti, Priyadharshini Gogu, Dhanashree N Sarwan, Manish Kumar Pathak, Prem Shankar Gupta, Ashish Ranjan Dwivedi, Prateek Pathak

Published in

Biochemical pharmacology. Pages 118379. Aug 21, 2026. Epub Aug 21, 2026.

Abstract

The mitogen-activated protein kinase (MAPK) signaling pathway is a central oncogenic signaling axis, with BRAF functioning as a critical regulatory node. The discovery of oncogenic BRAF mutations, most notably BRAF^V600E, enabled the development of targeted therapies that significantly improved clinical outcomes in several cancers. However, extensive preclinical and clinical investigations have revealed fundamental limitations of interpreting RAF signaling from a monomer-centric perspective. Rather than acting solely as an isolated kinase, BRAF exists in a dynamic equilibrium between inactive monomers and active dimers, with dimerization emerging as a major determinant of MAPK pathway output, therapeutic response, and resistance. In this review, we integrate structural, mechanistic, and translational evidence to establish BRAF dimerization as a central organizing principle of RAF signaling. These structural insights are placed in a disease context by examining how distinct classes of BRAF mutations constitutively active, dimer-dependent, or kinase-impaired converge on dimer-mediated MAPK activation. We further discuss molecular mechanisms that promote dimerization-driven therapeutic resistance, including alternative BRAF splicing, gene amplification, receptor tyrosine kinase RAS feedback activation, and scaffold-mediated stabilization of RAF dimers. Finally, we evaluate emerging therapeutic strategies targeting dimeric RAF complexes, including pan-RAF and dimer-compatible inhibitors, allosteric modulators, interface disruptors, and targeted protein degradation approaches, alongside mutation-class informed clinical trial designs and biomarker-adaptive strategies. Collectively, this review positions BRAF dimerization as a fundamental and therapeutically actionable feature of MAPK signaling, providing a structural and clinical framework for the development of durable RAF-targeted therapies beyond monomer inhibition.

PMID:
42628758
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.